Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 13/20 | 0.41 |
| ▸ | NOS3 | P29474 | 7/20 | 0.41 |
| ▸ | NOS1 | P29475 | 8/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL27928107 | 0.85 | CXCR4 (0.34) | NOS2NOS3NOS1 | |
| SCHEMBL8278194 | 0.84 | CCR1 (0.39) | — | |
| SCHEMBL12843993 | 0.80 | NOS2 (0.63) | NOS2NOS3NOS1 | |
| SCHEMBL5673354 | 0.78 | NOS2 (0.67) | NOS2NOS3NOS1 | |
| SCHEMBL5897870 | 0.77 | SLC6A3 (0.41) | — | |
| SCHEMBL7562734 | 0.77 | MAPT (0.34) | NOS2NOS3NOS1 | |
| SCHEMBL171325 | 0.75 | — | — | |
| SCHEMBL13729089 | 0.74 | CCR1 (0.32) | — | |
| SCHEMBL16840721 | 0.71 | NPC1 (0.50) | NOS2NOS3 | |
| SCHEMBL8835616 | 0.71 | PDE2A (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309240-B2 | Pyrazolopyridine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309240-B2 | Pyrazolopyridine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309240-B2 | Pyrazolopyridine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| EP-2640722-B1 | PYRAZOLOPYRIDINES AND THEIR USE AS TYK2 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-11-04 | — | — | EP | disclosed |
| EP-2640722-B1 | PYRAZOLOPYRIDINES AND THEIR USE AS TYK2 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-11-04 | — | — | EP | disclosed |
| US-20140171408-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8697708-B2 | Azabenzothiazole compounds, compositions and methods of use | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-15 | — | — | US | disclosed |
| US-20130252941-A1 | PYRAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-09-26 | — | — | US | disclosed |
| US-20130252941-A1 | PYRAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-09-26 | — | — | US | disclosed |
| US-20130252941-A1 | PYRAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-09-26 | — | — | US | disclosed |
| EP-2640722-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDINES AND THEIR USE AS TYK2 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-25 | — | — | EP | disclosed |
| CN-103313987-A | Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors | HOFFMANN LA ROCHE | 2013-09-18 | — | — | CN | disclosed |
| EP-2616072-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| CN-103209695-A | Azabenzothiazole compounds, compositions and methods of use | HOFFMANN LA ROCHE | 2013-07-17 | — | — | CN | disclosed |
| US-20120202788-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| WO-2012066061-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDINES AND THEIR USE AS TYK2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012066061-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDINES AND THEIR USE AS TYK2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012035039-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252941-A1 | PYRAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | P2RX5, P2RX4, P2RY1 | NOS2 3719/4885NOS3 3323/4885NOS1 3515/4885 |
| US-20140171408-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F12, CHRM1, NPY1R | NOS2 2303/4885NOS3 3275/4885NOS1 2434/4885 |
| US-20120202788-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F12, CHRM1, NPY1R | NOS2 2303/4885NOS3 3275/4885NOS1 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.